দেশ: আর্মেনিয়া
ভাষা: ইংরেজি
সূত্র: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
calcium, vitamin D3, magnesium, zinc, copper, manganese, boron
Contract Pharmacal Corporation
առկա չէ (A12AX)
calcium, vitamin D3, magnesium, zinc, copper, manganese, boron
500mg+ 400IU+ 40mg+ 7,5mg+ 1mg+ 1,8mg+ 250mcg
tablets film-coated
(30) and (60) in plastic container
OTC
Registered
2017-07-10
2. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT CALCEMIN SILVER QUALITATIVE AND QUANTITATIVE COMPOSITION 1 film-coated tablet contains: Calcium (citrate and carbonate) 500 mg Vitamin D3 (cholecalciferol) 400 lU Magnesium (in the form of magnesium oxide) 40 mg Zinc (in form of zinc oxide) 7,5 mg Copper (in form of copper oxide) 1 mg Manganese (in form of manganese sulfate) 1,8 mg Boron (in form of sodium borate) 250 mcg PHARMACEUTICAL FORM Film-coated tablets CLINICAL PARTICULARS erapeutic lndications Calcemin Silver is used for prophylaxis of osteoporosis and other conditions characterized with calcium deficiency. It is recommended as a multimodality therapy for osteoporosis when calcium and Vitamin Dr deficiency is diagnosed. It is also used to reduce the risk of fractures and to make up calcium, vitamin D and minerals deficiencies in elderly people (over 50 years old). Posology and Method of Adminis tion Adults and children over 12years of age. 1 tablet two times daily at mealtimes. Duration of treatment have to be determined by physician. Treatment course may be repeated as appropriate. Patients with liver dysfunction; dose adjustments are not required Patients with impaired renal function: do not use Calcemin Silver in case of severe 3. 4. 4.1 4.2 renal impairment. l--l-J^,1,. ^^t:^^+^. ^^ ^ l-- --- t-,- --l ..lr- t-)^^-:l--!^ -----l- - triLieriy pAiieiiLS. See UOSiige l(Jl iiUults. rOSSl(Jle rlepllla[Otllil consideration. 4.3 Cantraindications l-r hypersensitivity to any components of the product; tl hypercalcaemia and/or conditions, which lead to hypercalciuria (e.g sarcoidosis, malignant hyperpa rathyroid ism) ; I hypercalciuria; ir severe renal impairment, hypercalcaemia and/or neoplasms, primary Page 1 of 6 4.4 al nephrolithiasis; n hypervitaminosis D; t.r children below 12 years of age. Specia/ Warnings and Precautions for IJse Consideration must be given to concomitant intake of vitamin D from al sources including dietary for the avoidance of overdosage. Total dose of 2500 mg of সম্পূর্ণ নথি পড়ুন